Trial Profile
A Multi-Center, Randomized, Double-blind, Placebo-controlled, Multi-Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of SHR-1314 With Expanded Dose Finding in Subjects With Moderate-to-severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Aug 2023
Price :
$35
*
At a glance
- Drugs Vunakizumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 07 Aug 2023 Status changed from recruiting to completed.
- 10 Jan 2022 Results (n=187) assessing efficacy and safety of vunakizumab in moderate-to-severe plaque psoriasis in part B of this study were published in the Journal of the American Academy of Dermatology.
- 02 Jan 2019 Planned number of patients changed from 40 to 194.